Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

C4671052- A Phase 1, Randomized, Fixed Sequence, Multiple-Dose, Open-Label Study to Estimate the Effect of Nirmatrelvir (PF-07321332)/Ritonavir on Rosuvastatin Pharmacokinetics in Healthy Adult Participants

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Pfizer Inc.

Enrolment target

Start

24 May 2023

AUCinf and Cmax of rosuvastatin

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.